Geriatrik ve Non-Geriatrik Yoğun Bakım Hastalarında Kolistin İlişkili Nefrotoksisite: Retrospektif Kohort Çalışması

Year 2018, Volume: 28 Issue: 4, 141 - 145, 01.12.2018

Yeşim Şerife Bayraktar İpek Duman Ateş Duman

Abstract

Amaç: Kolistin kolistimetat sodyum son yıllarda çoklu ilaç direnci gösteren gram negatif bakterilerin oluşturduğu nozokomiyal enfeksiyonların tedavisinde kullanılmaktadır. Kolistin kullanımı sonucu gelişen ciddi advers etkiler arasında nefrotoksisite önemli bir yer tutar. Geriatrik hastalarda kolistin ve nefrotoksisite ilişkisine yönelik çalışmalar kısıtlıdır. Amacımız Yoğun Bakım Ünitesinde Acinetobacter baumannii enfeksiyonu nedeniyle kolistin tedavisi alan geriatrik ≥65 yaş ve nongeriatrik

Keywords

geriatrik, kolistin, nefrotoksisite, yoğun bakım

References

• Lim LM, Ly N, Anderson D, Yang JC, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279-91.
• Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized co- listin in the treatment of pneumonia due to multidrug-re- sistant Acinetobacter baumannii and Pseudomonas aerugi- nosa. Clin Infect Dis 2005;41:754-7.
• Korkmaz Ekren P, Töreyin ZN, Berk Takır H, et al. Evalu- ation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia. Tuberk Toraks 2017;65:271-81.
• Pintado V, San Miguel LG, Grill F, et al. Intravenous co- listin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90.
• Falagas ME, Fragoulis KN, KasiakouSK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colis- tin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-7.
• Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Sa- fety and efficacy of intravenous colistin (colistin methane sulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297- 300.
• Aydın M, Ergönül Ö, Azap A, et al. Rapid emergence of co- listin resistance and its impact on fatality among healthca- re-associated infections. J Hosp Infect 2018;98:260-3.
• Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug resistant Pseudo- monas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6.
• Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimic- rob Agents Chemother 2003;47:2659-62.
• Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85.
• Temocin F, Erdinc S, Tulek N, et al. Incidence and risk fac- tors for colistin-associated nephrotoxicity. Jpn J Infect Dis 2015;68:318-20.
• Phe K, Shields RK, Tverdek FP, et al. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohortstudy. J Antimicrob Chemother 2016;71:3585-7.
• Omrani AS, Alfahad WA, Shoukri MM, et al. High döşe intravenous colistin methane sulfonate therapy is associa- ted with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015;14:3.
• Özkarakaş H, Köse I, Zincirlioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critical- ly ill patients. Turk J Med Sci 2017;47:1165-72.
• Aydoğan BB, Yıldırım F, Zerman A, et al. Colistin nephro- toxicity in the ICU: Is it different in the geriatric patients? Aging Clin Exp Res 2018;30:573-80.
• Sriswat N, Hoste EE, Kellum JA. Modern classification of kidney injury. Blood Purif 2010;29:300-7.
• Strand K, Flaaten H. Severity scoring in the ICU: a review. Acta Anaesthesiol Scand 2008;52:467-78.
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large aca- demic health system. Clin Infect Dis 2011;53:879-84.
• Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colisti- methate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
• Phe K, Lee Y, Mc Daneld PM, et al. Invitro assessment and multicenter cohort study of comparative nephrotoxicity ra- tes associated with colistimethate versus polymyxin B the- rapy. Antimicrob Agents Chemother 2014;58:2740-6.
• Hassan MM, Gaifer Z, Al-Zakwani I. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodi- um. Int J Clin Pharm 2018;40:444-9.